Risankizumab Concentration but not IL-22 Levels are Associated With Clinical and Biochemical Remission in Patients With Crohn's Disease.
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
04 May 2024
04 May 2024
Historique:
received:
22
12
2023
revised:
20
03
2024
accepted:
26
03
2024
pubmed:
6
5
2024
medline:
6
5
2024
entrez:
5
5
2024
Statut:
aheadofprint
Résumé
Risankizumab (RZB) is a monoclonal antibody that targets the p19 subunit of interleukin (IL)-23.
Identifiants
pubmed: 38705437
pii: S1542-3565(24)00402-6
doi: 10.1016/j.cgh.2024.03.039
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.